Pharmacy evidence record · researched 2026-08-20
Apothecary Pharma, LLC
FDA documented Semaglutide Injection 2.5 mg/mL in the facility's 2025 inspection and warning letter.
FDA documented Tirzepatide Injection 10 mg/mL in the facility's 2025 inspection and warning letter.
FDA's 2025 records establish historical production and labeling, not current sale or availability in 2026.
Regulatory compliance
A pathway label describes which federal rules apply — it is not a quality claim.
Section 503A
The exact Cary facility is verified by FDA as a 503B outsourcing facility; no separate 503A facility classification was established.
Section 503B
FDA's current weekly registry contained the exact legal entity and Cary facility.
Telehealth providers
Clinic Scout links a provider only when an explicit source names the relationship.
Regulatory history
FDA's current 503B registry, Form FDA 483, and warning letter were verified. Warning-letter closeout status and state-board actions were not established.
U.S. Food and Drug Administration · 2025-05-15
FDA issued inspectional observations after a May 12-15, 2025 inspection of the Cary outsourcing facility.
inspectional_observations_not_final_agency_determinationU.S. Food and Drug Administration · 2025-12-01
FDA stated that products failed to meet 503B conditions and cited adulteration, unapproved-new-drug, and misbranding violations.
issued_closeout_unverifiedNo Clinic Scout patient reviews are published for this pharmacy. Submissions go through manual moderation before anything appears here.
What this record verifies for you
Each line traces to a citation in the source list below — read the exact captured wording before relying on it.
No superiority claim is made for review volume, ratings, or patient sentiment.
Located in the heart of Raleigh's Research Triangle, Apothecary Pharma is dedicated to addressing national medication shortages with precision and care. Our microbiologists and staff are leaders in the pharmaceutical compounding industry, specializing in producing high-quality sterile and non-sterile medications that meet the rigorous standards set by the FDA and adhere to cGMP guidelines.
Updated as of 8/18/2026
Apothecary Pharma, LLC, Cary, NC
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance.
From May 12, 2025, to May 15, 2025, FDA investigators inspected your facility, Apothecary Pharma, LLC located at 1913 Evans Road, Cary, NC 27513.
Some of your facility’s drug products, such as Tirzepatide Injection 10 mg/mL and Semaglutide Injection 2.5 mg/mL, did not include the following information on the label: a list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient.
During the inspection, FDA investigators noted that drug products produced by your facility failed to meet the conditions of section 503B.
GLP Clinic Scout does not issue a blanket legitimacy verdict. This research record preserves 7 dated first-party or regulator citation(s), 2 regulatory/action record(s), and 5 explicitly unresolved field(s). Review the cited evidence and current license status before making a decision.
Weekly price watch
One useful comparison each week. No spam, no sold lists, and you can unsubscribe anytime.